Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | May 20, 2026 | May 22, 2026 |
| Elevance Health, Inc.ELV · Entity 2934 | Director | May 13, 2026 | May 15, 2026 |
| FRACTYL HEALTH, INC.GUTS · Entity 6700 | Director | June 11, 2025 | June 13, 2025 |
| Hudson Executive Investment Corp. IIHCII · Entity 130674 | Director | April 13, 2021 | April 14, 2021 |
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Director | June 16, 2020 | June 18, 2020 |
| SQZ Biotechnologies CoSQZ · Entity 112267 | Director · 10% owner | June 14, 2023 | June 15, 2023 |
| Talkspace, Inc.HEC · Entity 22747 | Director | June 08, 2020 | June 08, 2020 |
| X4 Pharmaceuticals, IncASNS · Entity 5638 | Director | June 05, 2018 | June 07, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,049 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 838 · Balance 24,049 F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $298.48 · Expires 2036-05-20 | Direct | 1,802 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 1,802 · Balance 1,802 F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
Elevance Health, Inc.
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 781 |
Reported balance
After 2026-05-13 transaction · row 1
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 563 · Balance 781 F1: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program. F2: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.
F2: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.
FRACTYL HEALTH, INC.
Report date June 11, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2035-06-10 | Direct | 22,500 |
Reported balance
After 2025-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-11 · Grant · Acquired 22,500 · Balance 22,500 F1: The stock option was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. The stock option will vest and become exercisable in a single installment on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the first anniversary of the grant in each case subject to continued service on the Issuer's board of directors as a non-employee director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. The stock option will vest and become exercisable in a single installment on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the first anniversary of the grant in each case subject to continued service on the Issuer's board of directors as a non-employee director through the vesting date.
Hudson Executive Investment Corp. II
Report date April 13, 2021 · Filed April 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2021-04-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-13 · Purchase · Acquired 20,000 · Balance 20,000 F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-251848) (the "Registration Statement") and have no expiration date |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-251848) (the "Registration Statement") and have no expiration date
Korsana Biosciences, Inc.
Report date June 16, 2020 · Filed June 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2030-06-16 | Direct | 10,000 |
Reported balance
After 2020-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-16 · Grant · Acquired 10,000 · Balance 10,000 F1: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.
SQZ Biotechnologies Co
Report date June 14, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2033-06-13 | Direct | 39,875 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 39,875 · Balance 39,875 F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.
Talkspace, Inc.
Report date June 08, 2020 · Filed June 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-06-08 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-238583) (the "Registration Statement") and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-238583) (the "Registration Statement") and have no expiration date.
X4 Pharmaceuticals, Inc
Report date June 05, 2018 · Filed June 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.99 · Expires 2028-06-04 | Direct | 10,000 |
Reported balance
After 2018-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-05 · Grant · Acquired 10,000 · Balance 10,000 F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Blue Buffalo Pet Products, Inc.
Report date April 24, 2018 · Filed April 24, 2018
Section 16 reporting ended · disclosed 2018-04-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-04-24 transaction · row 1
1 source rowRow 1 · 2018-04-24 · Disposition to issuer · Disposed 14,819 · Balance 0 F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").
F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes.
Camp4 Therapeutics Corp
Report date September 11, 2025 · Filed September 11, 2025
Jointly reported with Polaris Management Co. VII, L.L.C., Polaris Partners VII, L.P., Polaris Entrepreneurs' Fund VII, L.P., Polaris Partners X, L.P., Polaris Partners GP X, L.L.C., Chee Brian
Section 16 reporting ended · disclosed 2025-09-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,825,500 |
Reported balance
After 2025-09-11 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2025-09-11 · Purchase · Acquired 1,221,721 · Balance 2,825,500 F1: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share. F2: The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 197,661 |
Reported balance
After 2025-09-11 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2025-09-11 · Purchase · Acquired 85,468 · Balance 197,661 F1: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share. F3: The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 909,090 |
Reported balance
Holding disclosure · report date 2025-09-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 909,090 F4: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share.
F2: The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F3: The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F4: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
IRONWOOD PHARMACEUTICALS INC
Report date April 01, 2019 · Filed April 03, 2019
Section 16 reporting ended · disclosed 2019-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 38,242 |
Reported balance
After 2019-04-01 transaction · row 1
1 source rowRow 1 · 2019-04-01 · Disposition to issuer · Disposed 4,056 · Balance 38,242 F1: Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock.
PFIZER INC
Report date December 31, 2013 · Filed January 03, 2014
Section 16 reporting ended · disclosed 2014-01-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock Units SSPSEC Table II · derivative / convertible security | Direct | 5,075 |
Reported balance
After 2013-12-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2013-12-31 · Grant · Acquired 59 · Balance 5,075 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2021 Filed Dec 23, 2021 22:15 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | Exercise / conversionStock Option · Derivative | 6,581 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001209191-21-071110 · doc4.xml · derivative · entry 11 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,949 Underlying: Common Stock · 6,581 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Options were exercised and held for tax planning purposes. F10 · derivative.exercise_date: The option vests and becomes exercisable in 48 equal monthly installments commencing on July 5, 2019. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 22:15 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | Exercise / conversionStock Option · Derivative | 7,458 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001209191-21-071110 · doc4.xml · derivative · entry 10 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,072 Underlying: Common Stock · 7,458 shares Expires 2029-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Options were exercised and held for tax planning purposes. F9 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying securities on February 1, 2020 and in 36 equal monthly installments thereafter. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 22:15 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | Exercise / conversionStock Option · Derivative | 10,091 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001209191-21-071110 · doc4.xml · derivative · entry 9 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439 Underlying: Common Stock · 10,091 shares Expires 2028-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Options were exercised and held for tax planning purposes. F8 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying securities on January 23, 2019 and in 36 equal monthly installments thereafter. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 22:15 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | Exercise / conversionCommon Stock | 6,581 | $4.59 | $30,206.79 |
DisclosureSEC source: 0001209191-21-071110 · doc4.xml · nonDerivative · entry 3 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Options were exercised and held for tax planning purposes. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 22:15 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | Exercise / conversionCommon Stock | 7,458 | $4.59 | $34,232.22 |
DisclosureSEC source: 0001209191-21-071110 · doc4.xml · nonDerivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Options were exercised and held for tax planning purposes. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 22:15 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | Exercise / conversionCommon Stock | 10,091 | $2.02 | $20,383.82 |
DisclosureSEC source: 0001209191-21-071110 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Options were exercised and held for tax planning purposes. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 22:15 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | PurchaseCommon Stock | 1,850 | $10.94 | $20,239.00 |
DisclosureSEC source: 0001209191-21-069790 · doc4.xml · nonDerivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,850 F2 · ownership.nature: These shares are held in trust 2 for the benefit of a child of the reporting person. The reporting person's spouse has investment authorization over the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 22:15 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | PurchaseCommon Stock | 1,850 | $10.88 | $20,128.00 |
DisclosureSEC source: 0001209191-21-069790 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,850 F1 · ownership.nature: These shares are held in trust 1 for the benefit of a child of the reporting person. The reporting person's spouse has investment authorization over the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 27, 2021 Filed Oct 29, 2021 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 1,814 | $0.00 Strike: $191.16 | $0.00 |
DisclosureSEC source: 0001735276-21-000086 · edgardoc.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,814 Underlying: Common Stock · 1,814 shares Expires 2031-10-26 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 4,032 | $0.00 Strike: $171.95 | $0.00 |
DisclosureSEC source: 0001735276-21-000068 · edgardoc.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032 Underlying: Common Stock · 4,032 shares Expires 2031-07-14 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:16 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 10,500 | $0.00 Strike: $13.57 | $0.00 |
DisclosureSEC source: 0001209191-21-041541 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2031-06-14 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 15, 2022 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders following the date of grant, in each case subject to the Reporting Person's continued service on the Board. Read SEC document |
| April 13, 2021 Filed Apr 14, 2021 20:44 UTC | Hudson Executive Investment Corp. II HCII · Entity 130674 | PurchaseClass B Common Stock · Derivative | 20,000 | $0.00 | $58.00 |
DisclosureSEC source: 0000899243-21-015821 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Class A Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-251848) (the "Registration Statement") and have no expiration date F1 · derivative.exercise_date: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-251848) (the "Registration Statement") and have no expiration date F1 · derivative.expiration_date: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-251848) (the "Registration Statement") and have no expiration date Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionSeries D Convertible Preferred Stock · Derivative | 93,279 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · derivative · entry 17 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 98,222 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · ownership.nature: These shares are held of record by LS Polaris Innovation Fund, L.P. ("LSPIF"). LS Polaris Innovation Fund GP, L.L.C. ("LSPIF GP") is the general partner of LSPIF. The Reporting Person is the sole managing member of LSPIF GP. Each of LSPIF GP and the Reporting Person may be deemed to have sole investment, voting and dispositive power over these shares. LSPIF GP and the Reporting Person disclaim beneficial ownership of the shares held by LSPIF and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionSeries D Convertible Preferred Stock · Derivative | 348,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · derivative · entry 16 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 367,207 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. F4 · ownership.nature: These shares are held of record by Polaris Partners VII, L.P. ("PP VII"). PMC VII is the general partner of PP VII. The Managing Members are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionSeries D Convertible Preferred Stock · Derivative | 24,396 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · derivative · entry 15 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 25,690 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: These shares are held of record by Polaris Entrepreneurs' Fund VII, L.P. ("EF VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of EF VII. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren (the "Managing Members") are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII. F3 · ownership.nature: Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionSeries C Convertible Preferred Stock · Derivative | 21,087 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · derivative · entry 14 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionSeries C Convertible Preferred Stock · Derivative | 168,698 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · derivative · entry 13 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 177,638 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · ownership.nature: These shares are held of record by LS Polaris Innovation Fund, L.P. ("LSPIF"). LS Polaris Innovation Fund GP, L.L.C. ("LSPIF GP") is the general partner of LSPIF. The Reporting Person is the sole managing member of LSPIF GP. Each of LSPIF GP and the Reporting Person may be deemed to have sole investment, voting and dispositive power over these shares. LSPIF GP and the Reporting Person disclaim beneficial ownership of the shares held by LSPIF and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionSeries C Convertible Preferred Stock · Derivative | 630,672 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · derivative · entry 12 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 664,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. F4 · ownership.nature: These shares are held of record by Polaris Partners VII, L.P. ("PP VII"). PMC VII is the general partner of PP VII. The Managing Members are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionSeries C Convertible Preferred Stock · Derivative | 44,120 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · derivative · entry 11 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 46,458 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: These shares are held of record by Polaris Entrepreneurs' Fund VII, L.P. ("EF VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of EF VII. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren (the "Managing Members") are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII. F3 · ownership.nature: Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionSeries B Convertible Preferred Stock · Derivative | 807,096 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · derivative · entry 10 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 849,872 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. F4 · ownership.nature: These shares are held of record by Polaris Partners VII, L.P. ("PP VII"). PMC VII is the general partner of PP VII. The Managing Members are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionSeries B Convertible Preferred Stock · Derivative | 56,462 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · derivative · entry 9 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 59,454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: These shares are held of record by Polaris Entrepreneurs' Fund VII, L.P. ("EF VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of EF VII. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren (the "Managing Members") are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII. F3 · ownership.nature: Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionSeries A Convertible Preferred Stock · Derivative | 412,608 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · derivative · entry 8 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 434,476 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. F4 · ownership.nature: These shares are held of record by Polaris Partners VII, L.P. ("PP VII"). PMC VII is the general partner of PP VII. The Managing Members are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionSeries A Convertible Preferred Stock · Derivative | 28,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · derivative · entry 7 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 30,392 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: These shares are held of record by Polaris Entrepreneurs' Fund VII, L.P. ("EF VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of EF VII. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren (the "Managing Members") are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII. F3 · ownership.nature: Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | PurchaseCommon Stock | 233,654 | $16.00 | $3,738,464.00 |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · nonDerivative · entry 6 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 2,549,306 F3 · ownership.nature: Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. F4 · ownership.nature: These shares are held of record by Polaris Partners VII, L.P. ("PP VII"). PMC VII is the general partner of PP VII. The Managing Members are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | PurchaseCommon Stock | 16,346 | $16.00 | $261,536.00 |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · nonDerivative · entry 5 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 178,340 F2 · ownership.nature: These shares are held of record by Polaris Entrepreneurs' Fund VII, L.P. ("EF VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of EF VII. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren (the "Managing Members") are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII. F3 · ownership.nature: Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionCommon Stock | 275,860 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · nonDerivative · entry 4 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 275,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · ownership.nature: These shares are held of record by LS Polaris Innovation Fund, L.P. ("LSPIF"). LS Polaris Innovation Fund GP, L.L.C. ("LSPIF GP") is the general partner of LSPIF. The Reporting Person is the sole managing member of LSPIF GP. Each of LSPIF GP and the Reporting Person may be deemed to have sole investment, voting and dispositive power over these shares. LSPIF GP and the Reporting Person disclaim beneficial ownership of the shares held by LSPIF and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionCommon Stock | 2,315,652 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · nonDerivative · entry 3 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 2,315,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. F4 · ownership.nature: These shares are held of record by Polaris Partners VII, L.P. ("PP VII"). PMC VII is the general partner of PP VII. The Managing Members are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionCommon Stock | 161,994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · nonDerivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 161,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: These shares are held of record by Polaris Entrepreneurs' Fund VII, L.P. ("EF VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of EF VII. David Barrett, Brian Chee, Amir Nashat and Bryce Youngren (the "Managing Members") are the managing members of PMC VII. The Reporting Person, a member of the Issuer's board of directors, holds an interest in PMC VII. F3 · ownership.nature: Each of the Managing Members and the Reporting Person, in their respective capacities with respect to PMC VII, may be deemed to have shared investment, voting and dispositive power over these shares. Each of PMC VII, the Managing Members and the Reporting Person disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionCommon Stock | 22,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030318 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 22:30 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 7,055 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-029974 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,055 Underlying: Common Stock · 7,055 shares Expires 2030-10-28 F1 · derivative.exercise_date: The option vests and becomes exercisable on October 29, 2021. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 20:50 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 4,581 | $0.00 Strike: $148.77 | $0.00 |
DisclosureSEC source: 0001735276-20-000076 · edgardoc.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,581 Underlying: Common Stock · 4,581 shares Expires 2030-07-01 Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 20:15 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001209191-20-037566 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 20:07 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $72.01 | $0.00 |
DisclosureSEC source: 0001735276-19-000066 · edgardoc.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-30 Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:59 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.95 | $0.00 |
DisclosureSEC source: 0001209191-19-034383 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-01 F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 20:13 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | PurchaseCommon Stock | 21,635 | $16.00 | $346,160.00 |
DisclosureSEC source: 0001209191-19-024236 · doc4.xml · nonDerivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Polaris Entrepreneurs' Fund VIII, L.P. Disclosed balance after: 21,635 F1 · shares: These shares were acquired from unaffiliated stockholders in a negotiated, private transaction. F3 · ownership.nature: The reportable securities are owned directly by Polaris Entrepreneurs' Fund VIII, L.P. ("PEF VIII"). PPGP VIII is the general partner of PEF VIII. The Reporting Person, a member of the Issuer's Board of Directors, is an interest holder of PPGP VIII. Each of the Reporting Person and the Managing Members, in their respective capacities with respect to PPGP VIII, may be deemed to have shared voting and dispositive power over the shares held by PEF VIII. Each of PPGP VIII, the Reporting Person and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 20:13 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | PurchaseCommon Stock | 604,482 | $16.00 | $9,671,712.00 |
DisclosureSEC source: 0001209191-19-024236 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Polaris Partners VIII, L.P. Disclosed balance after: 604,482 F1 · shares: These shares were acquired from unaffiliated stockholders in a negotiated, private transaction. F2 · ownership.nature: The reportable securities are owned directly by Polaris Partners VIII, L.P. ("PP VIII"). Polaris Partners GP VIII, L.L.C. ("PPGP VIII") is the general partner of PP VIII. The Reporting Person, a member of the Issuer's Board of Directors, is an interest holder of PPGP VIII. Each of David Barrett, Brian Chee, Amir Nashat and Bryce Youngren are the managing members of PPGP VIII (collectively, the "Managing Members"). Each of the Reporting Person and the Managing Members, in their respective capacities with respect to PPGP VIII, may be deemed to have shared voting and dispositive power over the shares held by PP VIII. Each of PPGP VIII, the Reporting Person and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:34 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 3,279 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023514 · doc4.xml · nonDerivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,508 F2 · shares: Represents shares of Cyclerion common stock granted to the reporting person as a result of adjustments to existing Ironwood shares of common stock made in connection with the Separation. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:34 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 4,229 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023514 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,229 F1 · shares: In connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"), the reporting person received Cyclerion shares representing an equitable adjustment of Ironwood shares held by the reporting person prior to the Separation. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:05 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Disposition to issuerClass A Common Stock | 4,056 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-023419 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,242 F1 · price: Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 20:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 183 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-020265 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,298 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:28 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 212 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063261 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,115 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 20:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 136 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-051466 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,903 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 20:19 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $105.26 | $0.00 |
DisclosureSEC source: 0001735276-18-000033 · edgardoc.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2028-06-19 Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 22:43 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 126 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038676 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,767 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:24 UTC | X4 Pharmaceuticals, Inc ASNS · Entity 5638 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.99 | $0.00 |
DisclosureSEC source: 0001209191-18-036350 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-04 F1 · derivative.exercise_date: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 21:30 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 16,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035251 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,641 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document |
| April 24, 2018 Filed Apr 24, 2018 20:52 UTC | Blue Buffalo Pet Products, Inc. BUFF · Entity 167336 | Disposition to issuerCommon Stock | 14,819 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-010663 · doc4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2 · price: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes. Read SEC document |
| November 15, 2017 Filed Dec 1, 2017 22:18 UTC | X4 Pharmaceuticals, Inc ASNS · Entity 5638 | GrantStock Option (right to buy) · Derivative | 7,324 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0000899243-17-027822 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,324 Underlying: Common Stock · 7,324 shares Expires 2027-11-14 F1 · security: Consists of an automatic stock option grant that was made on November 15, 2017, the date of the effectiveness of the registration statement for the issuer's initial public offering, under the issuer's director compensation program. F2 · derivative.exercise_date: The option becomes exercisable as to 33.3333% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. Read SEC document |
| November 15, 2017 Filed Mar 5, 2018 22:03 UTC Amendment | X4 Pharmaceuticals, Inc ASNS · Entity 5638 | GrantCommon Stock (right to buy) · Derivative | 25,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-18-016591 · doc4a.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-11-14 F1 · shares: Consists of an automatic stock option grant that was made pursuant to the issuer's director compensation policy on November 15, 2017, the date of effectiveness of the registration statement for the issuer's initial public offering. Under the terms of the policy, the Reporting Person received an option to purchase 25,000 shares. Due to a clerical error, the original Form 4 filed on December 1, 2017 erroneously reported an option grant of 7,324 shares. This Amendment to Form 4 is filed solely to correct the share number. F2 · derivative.exercise_date: The option becomes exercisable as to 33.3333% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 21:01 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $71.99 | $0.00 |
DisclosureSEC source: 0001553878-17-000031 · edgardoc.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2027-06-01 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.